Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABCL Stock Forecast 2026-2027
$6.16
Current Price
$2.06B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ABCL Price Targets
+111.0%
To High Target of $13.00
+78.6%
To Median Target of $11.00
+13.6%
To Low Target of $7.00
ABCL Price Momentum
-9.4%
1 Week Change
+13.2%
1 Month Change
+57.9%
1 Year Change
+80.1%
Year-to-Date Change
-27.0%
From 52W High of $8.44
+124.4%
From 52W Low of $2.75
📊 TOP ANALYST CALLS
Did ABCL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AbCellera is one of their latest high-conviction picks.
Latest ABCL Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ABCL has a bullish consensus with a median price target of $11.00 (ranging from $7.00 to $13.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $6.16, the median forecast implies a 78.6% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABCL Analyst Ratings
9
Buy
0
Hold
0
Sell
ABCL Price Target Range
Low
$7.00
Average
$11.00
High
$13.00
Current: $6.16
Latest ABCL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABCL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | Benchmark | Robert Wasserman | Buy | Upgrade | $11.00 |
| May 5, 2026 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Apr 10, 2026 | Jones Trading | Buy | Initiates | $N/A | |
| Nov 7, 2025 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Aug 8, 2025 | Stifel | Buy | Maintains | $N/A | |
| Jul 14, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Jul 7, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Assumes | $5.00 |
| May 16, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| May 9, 2025 | Stifel | Buy | Maintains | $N/A | |
| Apr 16, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Mar 3, 2025 | Benchmark | Hold | Reiterates | $N/A | |
| Feb 28, 2025 | Stifel | Buy | Maintains | $N/A | |
| Jan 8, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Nov 5, 2024 | Benchmark | Hold | Reiterates | $N/A | |
| Nov 5, 2024 | Stifel | Buy | Reiterates | $N/A | |
| Aug 20, 2024 | Benchmark | Hold | Downgrade | $N/A | |
| Jul 11, 2024 | Keybanc | Overweight | Maintains | $N/A | |
| May 8, 2024 | Keybanc | Overweight | Maintains | $N/A | |
| Feb 22, 2024 | Benchmark | Buy | Upgrade | $N/A | |
| Feb 21, 2024 | Stifel | Buy | Maintains | $N/A |
AbCellera Biologics Inc. (ABCL) Competitors
The following stocks are similar to AbCellera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AbCellera Biologics Inc. (ABCL) Financial Data
AbCellera Biologics Inc. has a market capitalization of $2.06B with a P/E ratio of -13.7x. The company generates $79.21M in trailing twelve-month revenue with a -181.7% profit margin.
Revenue growth is +96.3% quarter-over-quarter, while maintaining an operating margin of -691.8% and return on equity of -14.7%.
Valuation Metrics
Market Cap
$2.06B
Enterprise Value
$1.63B
P/E Ratio
-13.7x
PEG Ratio
2.1x
Price/Sales
25.7x
Growth & Margins
Revenue Growth (YoY)
+96.3%
Gross Margin
N/A
Operating Margin
-691.8%
Net Margin
-181.7%
EPS Growth
+96.3%
Financial Health
Cash/Price Ratio
+26.8%
Current Ratio
14.1x
Debt/Equity
14.9x
ROE
-14.7%
ROA
-10.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AbCellera Biologics Inc. (ABCL) Business Model
About AbCellera Biologics Inc.
What They Do
Develops therapeutic antibodies through innovative technology.
Business Model
The company utilizes a technology-driven platform that combines biology, computation, and engineering to discover therapeutic antibodies from natural immune responses. It monetizes its operations by partnering with pharmaceutical and biotechnology companies, offering its antibody discovery capabilities to help advance drug candidates into clinical development.
Additional Information
Founded in 2012 and based in Vancouver, AbCellera plays a crucial role in the biopharmaceutical industry, focusing on a wide range of diseases and targeting complex drug challenges. Its collaborations aim to enhance the development of new antibody-based medicines, thereby contributing to global healthcare advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
596
CEO
Dr. Carl L.G. Hansen Ph.D.
Country
Canada
IPO Year
2020
Website
www.abcellera.comAbCellera Biologics Inc. (ABCL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice
Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jul 07, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
AbCellera will report its Q2 2026 financial results on August 5, 2026.
Why It Matters
AbCellera's upcoming financial report on August 5, 2026, will provide insights into its performance and growth trajectory, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice
10 days ago
Quick Summary
AbCellera Biologics Inc. (ABCL) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters
The inquiry into AbCellera's potential as a top momentum stock signals heightened interest, which could affect trading volumes and stock price volatility, impacting investor strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
AbCellera has appointed Dr. Lynn Seely to its Board of Directors, potentially enhancing its leadership team and strategic direction.
Why It Matters
Dr. Seely's appointment may enhance AbCellera's strategic direction and innovation, potentially boosting investor confidence and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have shown performance metrics relative to their sector in 2023, indicating sector-specific trends. Further details are needed for specifics.
Why It Matters
Performance comparisons highlight relative strengths or weaknesses, influencing investment decisions and market sentiment regarding AbCellera and Agilon's growth potential within their sectors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ABCellera Biologics (ABCL) experienced significant trading volume recently. However, recent earnings estimate revisions may hinder its potential for short-term gains.
Why It Matters
ABCL's increased trading volume indicates heightened investor interest, but negative earnings estimate revisions may signal potential price declines, affecting investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Jazz Pharmaceuticals has partnered with AbCellera to develop T-cell engaging multispecific antibodies for cancer through a research collaboration and licensing agreement.
Why It Matters
The collaboration could enhance Jazz Pharmaceuticals' oncology portfolio, potentially leading to innovative treatments and increased market competitiveness, impacting stock performance positively.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About ABCL Stock
What is AbCellera Biologics Inc.'s (ABCL) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, AbCellera Biologics Inc. (ABCL) has a median price target of $11.00. The highest price target is $13.00 and the lowest is $7.00.
Is ABCL stock a good investment in 2027?
According to current analyst ratings, ABCL has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABCL stock?
Wall Street analysts predict ABCL stock could reach $11.00 in the next 12 months. This represents a 78.6% increase from the current price of $6.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AbCellera Biologics Inc.'s business model?
The company utilizes a technology-driven platform that combines biology, computation, and engineering to discover therapeutic antibodies from natural immune responses. It monetizes its operations by partnering with pharmaceutical and biotechnology companies, offering its antibody discovery capabilities to help advance drug candidates into clinical development.
What is the highest forecasted price for ABCL AbCellera Biologics Inc.?
The highest price target for ABCL is $13.00 from at , which represents a 111.0% increase from the current price of $6.16.
What is the lowest forecasted price for ABCL AbCellera Biologics Inc.?
The lowest price target for ABCL is $7.00 from at , which represents a 13.6% increase from the current price of $6.16.
What is the overall ABCL consensus from analysts for AbCellera Biologics Inc.?
The overall analyst consensus for ABCL is bullish. Out of 4 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are ABCL stock price projections?
Stock price projections, including those for AbCellera Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:01 AM UTC